Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cytori Therapeutics, Inc. (NASDAQ: CYTX).

Full DD Report for CYTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYTX)

Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
SAN DIEGO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will present at the 20 th Annual Rodman & Renshaw Global Investment Conference at 09:10 AM Eastern Time on Thursday, September 6, 2018. The presentation will take place in the ...
Source: GlobeNewswire
Date: August, 31 2018 09:00
Today's Research Reports on Stocks to Watch: Medtronic and Cytori Therapeutics
NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Medtronic shares hit a brand new high after announcing impressive first quarter results. Shares of Cytori Therapeutics also soared in Tuesday’s session despite any particular news. The company had reported its own earnings last week. RDI...
Source: ACCESSWIRE IA
Date: August, 22 2018 08:00
Turkey Fires Back With Tariffs (Wall Street Breakfast Podcast)
Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Today's top ...
Source: SeekingAlpha
Date: August, 15 2018 07:44
Wall Street Breakfast: Turkey Fires Back With Tariffs
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). A reeling Turkey has responded to U.S. tariffs with retaliatory duties on U.S. passenger cars, alcohol, tobacco, c...
Source: SeekingAlpha
Date: August, 15 2018 06:38
Cytori Therapeutics Inc (CYTX) CEO Marc Hedrick on Q2 2018 Results - Earnings Call Transcript
Cytori Therapeutics Inc (CYTX) Q2 2018 Earnings Conference Call August 14, 2018 05:30 PM ET Executives Marc Hedrick - President and CEO Tiago Girão - CFO Analysts Jason Kolbert - H.C. Wainwright Yale Jen - Laidlaw and Company Presentation Operator Good aftern...
Source: SeekingAlpha
Date: August, 14 2018 22:05
Cytori Therapeutics misses by $0.14, beats on revenue
Cytori Therapeutics (NASDAQ: CYTX ): Q2 EPS of -$0.59 misses by $0.14 . Revenue of $1.56B (+103900.0% Y/Y) beats by $1.56B . Press Release More news on: Cytori Therapeutics Inc, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: August, 14 2018 16:26
Cytori Reports Q2 2018 Business and Financial Results
SAN DIEGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q2 2018 financial results and provided updates on corporate activities. Q2 2018 net loss was $3.7 million, or $0.59 per share. Operatin...
Source: GlobeNewswire
Date: August, 14 2018 16:20
Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of “Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report. &...
Source: GlobeNewswire
Date: August, 09 2018 09:25
Cytori to Webcast Second Quarter Financial Results on August 14
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Tuesday, August 14, 2018 at 5:30 PM Eastern Time. The dial-in information is as follows:     ...
Source: GlobeNewswire
Date: August, 02 2018 16:01
Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO, July 24, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that its previously announced rights offering (“the Rights Offering”) expired on July 20, 2018 and such rights are no longer exercisable. Cytori accepted all valid subscription...
Source: GlobeNewswire
Date: July, 24 2018 07:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.320.31510.32350.31113,195
2018-12-120.3170.31830.32490.313566,872
2018-12-110.3250.3160.330.3172,906
2018-12-100.320.32010.32410.3133218,735
2018-12-070.32630.32790.3450.31598,185

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1318,46960,73030.4117Cover
2018-12-125,75916,62434.6427Cover
2018-12-1125,43453,89547.1918Short
2018-12-1033,91768,86849.2493Short
2018-12-071,7296,43726.8603Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYTX.


About Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Logo for Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Not available

 

Contact Information

 

 

Current Management

  • Christopher J. Calhoun / President, CEO
  • Ari E. Bizimis / CFO

Current Share Structure

  • Market Cap: $17,066,536 - 05/15/2018
  • Issue and Outstanding: 59,819,615 - 01/31/2018

 


Recent Filings from (NASDAQ: CYTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 06 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 06 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 09 2018

 

 


Daily Technical Chart for (NASDAQ: CYTX)

Daily Technical Chart for (NASDAQ: CYTX)


Stay tuned for daily updates and more on (NASDAQ: CYTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CYTX and does not buy, sell, or trade any shares of CYTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/